Alterity Therapeutics Receives Positive Regulatory Feedback Following Type C Meeting With FDA Regarding Planned Phase 3 Development Program For ATH434 In MSA

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has received positive feedback from the U.S. Food and Drug Administration (FDA) following a Type C Meeting regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA). The feedback supports Alterity's plans related to clinical pharmacology and non-clinical development, indicating alignment with the FDA on the readiness to initiate a pivotal trial.